Comparative Pharmacology
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus AMINOSYN 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINESS 5 2 ESSENTIAL AMINO ACIDS W HISTADINE versus AMINOSYN 3 5 IN PLASTIC CONTAINER.
AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE vs AMINOSYN 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
Intravenous infusion: 500 mL of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
None Documented
None Documented
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution